MEI Pharma, Inc. (NASDAQ:MEIP) (the “Company”) today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) (“Infinity”) in connection with the Company’s special meeting on July 23, 2023, at 10:00 a.m. Eastern Time:
Dear Fellow MEI Shareholders,
We have extended the opportunity for shareholders to vote FOR our pending transaction with Infinity Pharmaceuticals, Inc. If you haven’t voted yet, you can still do so today.
Through this transaction, we are creating a combined company that is well capitalized and positioned to advance a diversified pipeline of three clinical-stage development programs.
On a recent webcast, Dr. Ezra Cohen, a leading medical oncologist and cancer researcher, along with other medical experts, discussed the market opportunity and patient needs for therapies, such as Eganelisib, Voruciclib and ME-344. We encourage shareholders to listen to the webcast to learn more about these important and potentially value-creating therapies here.
Don’t miss out. Independent leading proxy advisory firms ISS and Glass Lewis both recognize the strategic benefits of the transaction and recommend shareholders vote FOR the Infinity transaction. In fact, as recently as recently as July 14, 2023, ISS reiterated its recommendation.
As a reminder, a vote FOR the transaction is a vote FOR:
- Creating a diversified pipeline of three clinical-stage development programs that have the potential, in combination with current therapies, to overcome known resistance mechanisms.
- Providing potential opportunities for near-term value creation from upcoming data that is expected to be released over the next approximate 6-24 months.
- Benefiting from the clinical development and regulatory expertise of the MEI and Infinity teams in developing pharmaceutical products to treat cancer.
We encourage you to vote FOR the transaction and participate in the upside potential of a combined company that is poised to create value for shareholders and deliver improved therapeutic options for patients.
Thank you for your support,
MEI Board of Directors
YOUR VOTE IS IMPORTANT!
VOTE “FOR” THE TRANSACTION WITH INFINITY PHARMACEUTICALS TODAY
The record date for shareholders entitled to vote at the special meeting remains the close of business on May 24, 2023.
Shareholders who have questions or need assistance voting your shares, please contact Alliance Advisors, MEI’s proxy solicitor:
